

# Epidemiological Analysis of Confirmed Mpox Cases in Burundi, July to September 2024

Alexis Nizigiyimana<sup>1#</sup>, Francois Ndikumwenayo<sup>2</sup>, Martin Manirakiza<sup>2,3</sup>, Monique van Lettow<sup>4,5</sup>,  
Adrienne K. Chan<sup>5,6,7</sup>, Laurens Liesenborghs<sup>8</sup>, Placide Mbala-Kingebeni<sup>9,10</sup>, Anne W. Rimoin<sup>11</sup>,  
Isaac I. Bogoch<sup>12</sup>, Jason Kindachuk<sup>13,14#</sup>

<sup>1</sup>Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, QC, Canada

<sup>2</sup>University of Burundi, Bujumbura, Bujumbura, Burundi

<sup>3</sup>Burundi NCD Alliance, Bujumbura, Burundi

<sup>4</sup>Madiro, Toronto, Canada.

<sup>5</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

<sup>6</sup>Infection Prevention and Control, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

<sup>7</sup>Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON, Canada

<sup>8</sup>Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

<sup>9</sup>Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo

<sup>10</sup>Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa

<sup>11</sup>Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA

<sup>12</sup>Department of Medicine, University of Toronto, Toronto, ON, Canada

<sup>13</sup>Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada

<sup>14</sup>Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

#Corresponding Authors: Alexis Nizigiyimana ([alexis.nizigiyimana@madiro.org](mailto:alexis.nizigiyimana@madiro.org)); Jason Kindachuk ([Jason.Kindachuk@umanitoba.ca](mailto:Jason.Kindachuk@umanitoba.ca))

## ABSTRACT

This study analyzes mpox cases in Burundi from July to September 2024, following the introduction of Clade Ib. During this time, 25.4% of 607 samples tested positive via PCR. Children under 15 comprised 55.2% of cases, with a higher proportion of female children testing positive. Geographic analysis demonstrates case concentration in Bujumbura Mairie (59.1%). These findings highlight the importance of age- and sex-specific interventions for outbreak containment and the need for targeted public health strategies in Burundi.

## INTRODUCTION

Mpox is a zoonotic viral infectious disease first identified in the Democratic Republic of the Congo (DRC) in 1970 (1-3). Monkeypox virus (MPXV) historically circulated in the tropical forest regions of Central and West Africa, where it is considered endemic (4, 5). The virus is subclassified into two clades: clade I, formerly known as the Congo Basin (Central Africa) clade, and clade II, formerly known as the West African clade. Clade II is further subdivided into two subclades: IIa and IIb, with the latter responsible for the global epidemic in 2022 (6, 7).

Historically, zoonosis has been the primary driver of MPXV infections in humans with secondary infections through human-to-human contact. However, Clade IIb MPXV infections during the 2022 global epidemic were linked primarily to sustained human-to-human transmission (8) including within the men who have sex with men (MSM) community (9). The emergence of Clade Ib MPXV in South Kivu, DRC, has demonstrated similar transmission characteristics that have included linkage to sexual networks and sustained human-to-human transmission (10).

However, unlike Clade IIb infections, Clade Ib mpox cases have not been overrepresented among males in South Kivu. Further, recent expansion of Clade Ib into North Kivu, DRC, has included probable transmission through non-sexual or intimate contacts that have included children. While there may be reporting biases complicating a more wholesome understanding of mpox epidemiology, containment and mitigation strategies in this ongoing public health emergency must consider these clade-specific demographic considerations for mpox acquisition.

The ongoing historic national outbreak in DRC has resulted in international expansion of Clade Ib MPXV to multiple countries within the region including Kenya, Rwanda, Uganda, and

Burundi. This has resulted in the first declaration of a public health emergency of continental security by the Africa CDC and the second declaration of a public health emergency of international concern for mpox by the World Health Organization. Concerningly, mpox cases in Burundi have demonstrated an increasing trajectory following Clade Ib introduction that has included broad geographic expansion to many provinces. Here, we provide an analysis of demographic and epidemiological considerations for mpox in Burundi using mpox case data from July to September 2024.

## RESULTS

We analyzed national mpox testing and demographic data acquired in Burundi from 03 July 2024 to 09 September 2024. During this period, 14 samples were tested in July, with 349 tested in the month of August, and 244 for September up to 09 September 2024 for a total of 607 samples tested by PCR for MPXV (Table 1). Of these, men comprised 305 samples (50.2%) and women comprised 302 samples (49.8%). For all samples, 154 samples (25.4%) tested positive, 448 samples (73.8%) tested negative, and 5 samples (0.8%) were indeterminate. Of the positive samples, most positive tests were from men (80/154; 51.9%) with women comprising 48.1% of positive cases (74/154). Negative samples were nearly evenly split between men (223/448; 49.8%) and women (225/448; 50.2%).

In analyzing age demographics, the median age of all individuals tested was 7 years (IQR: 2-18 years) (Table 2). For mpox-positive cases, the median age was 9.5 years (IQR: 3-25 years). For males, the median age of positive cases was 17.5 years (IQR: 4.8-28.5 years). In contrast, the median age of females who tested positive was 6 years (IQR: 2-20 years). The median age of males and females that tested negative were similar at 7 years (IQR: 2-17.5 years) and 6 years (IQR: 2-14 years), respectively.

In analyzing overall age demographics with mpox positivity, children <15 years comprised the majority of all positive cases (85/154; 55.2%) (Table 3). This was followed by those aged 15-30 years (45/154; 29.2%) and lastly individuals 30+ years (24/154; 15.6%). When factoring in sex and age with mpox positivity, there was a greater proportion of females (47/154; 30.5%) than males (38/154; 24.7%) for children <15 years. Proportions were comparable between females

and males for those 15-30 years at 13.6% (21/154) and 15.6% (24/154), respectively. For those aged 30+ years, there was a greater proportion of males (18/154; 11.7%) than females (6/154; 3.9%).

We also assessed the geographic distribution of positive cases in Burundi (Table 4). Mpox positive cases were identified from 14 provinces in Burundi with the majority of positive cases identified in Bujumbura Mairie (91/154; 59.1%) followed by Bubanza, Bujumbura, and Kayanza with 10 cases reported from each (6.5% of positive cases). Associations between geographic regions and age distribution of cases were limited due to the high proportion of overall mpox cases reported from Bujumbura Mairie and much lower proportions in any of the other provinces reporting. We did analyze age demographics in Bujumbura Mairie as compared to the complete national data set. When focusing on Bujumbura Mairie, where 59.1% (91/154) of all mpox cases were reported, children <15 years comprised 45% of cases (44/91), followed by those aged 15-30 years at 35.2% (32/91) and lastly those 30+ years with 16.5% of cases (15/91). When combining positive case data from all other provinces (63 cases total), children <15 years comprised the highest proportion of all cases at 65.1% (41/63), followed by those aged 15-30 years at 20.6% (13/63) and those 30+ years at 14.3% (9/63).

Hospitalization data for confirmed mpox cases was available up to 25 September 2024 for a total of 254 cases with 247 requiring care for more than one day (Table 5). Of these, 45 currently remain in hospital, including 20 females and 25 males. The median age of those hospitalized was 19 (IQR: 8-28) with females being younger than males at 16 years (IQR: 7-25) versus 22 (IQR: 8-32), respectively. The overall duration of hospital admission was 8 days (IQR: 6-12) with females and males having very similar hospitalization durations at 8 days (IQR: 5-9.8) and 9 days (IQR: 6-12), respectively. In regard to comorbidities among those hospitalized, none were noted for the majority of the patients including 107 females and 124 males (231 cases total). Among the hospitalized female cases, HIV positivity was noted among 6 patients, followed by hypertension (3 cases), asthma (2 cases), and diabetes (1 case). For the hospitalized male cases, the most prominent comorbidities were hypertension (4 cases), asthma (3 cases), diabetes (3 cases), and HIV (1 case).

## DISCUSSION

From January 2023 to present, broad geographic expansion of Clade I MPXV in the DRC has resulted in the largest mpox outbreak in recorded history among all endemic countries. Concerningly, this national outbreak has included the expansion of MPXV to all provinces in DRC as well as the emergence of a new virus subclade, Clade Ib, associated with sustained human-to-human transmission (10). While first reported in South Kivu province, DRC, Clade Ib has undergone rapid regional expansion that has included introduction to North Kivu, DRC (11), as well as dissemination to neighbouring countries in East Africa, including Uganda, Rwanda, Kenya, and most notably Burundi.

Here, we provide the first assessments of demographic, epidemiological, and hospitalization data from suspected and confirmed mpox cases in Burundi from 03 July 2024 to 09 September 2024. During this period, 607 suspected mpox cases underwent PCR testing with an overall mpox positivity rate of 25.4%. This report provides important insights into Clade Ib mpox cases. Our analysis of sex and mpox positivity did not demonstrate a strong indication of sex-specific determinates with both a 0.5-1% difference between males and females when considering PCR positive or negative results only. However, sex-specific differences were present when considering age, mpox positivity, and hospitalization. While the median ages of males and females were very similar among mpox negative cases (7 years and 6 years, respectively) there was a large median age difference between males and females for mpox positive cases (17.5 years and 6 years, respectively), highlighting potential disparate sex-based epidemiologic risk factors for infection. Further segregation of the data into age range groups showed that females had a higher PCR positivity as compared to males for children <15 years whereas these trends were reversed when considering those aged 30+ years. Males also had a slightly higher mpox positivity percentage when considering those aged 15-30 years; however, this difference was lowest amongst the age groupings. When considering hospitalization, females with mpox tended to be younger than males (16 years compared to 22 years); however, the durations of hospitalization were very similar at 8 days and 9 days, respectively. No fatalities were noted among these patients though there were individuals still hospitalized at the time of this reporting. Thus, this early data suggests that female mpox patients requiring hospitalization tended to be younger than their male counterparts, there were no obvious indications of differences in outcome or severity. These data provide important considerations for mpox response and containment efforts in Burundi. Notably, this early epidemiological data suggests that female

children may be at higher risk for infection acquisition than their male counterparts whereas males >30 years appear to be at higher risk for infection than females. Whether these data are reflective of certain activities or behaviours associated with greater risk of MPXV infection across sex and age groups needs to be addressed. An additional important consideration from this data is that while mpox cases in Burundi were overrepresented among children <15 years, the median age of hospitalization for both males and females was >15 years, unlike Clade Ia where the highest morbidity and mortality have been among children historically. Considerations should include assessment of potential reporting biases by sex and age as well as activities among these groups that may be associated with higher infection risks (e.g. household caregiving, contact with contaminated materials). It is also prudent to consider recent data for Clade Ib infections from North Kivu which included probable non-sexual (intimate) contact-based transmission events within and outside of households, including children (11). Thus, community engagement and messaging activities in Burundi should consider these early associations between mpox positivity status, sex, and age.

Geographic associations with mpox cases were perhaps unsurprising as the majority of cases were identified in Bujumbura Mairie Province (59.1%), which includes the city of Bujumbura alone. The remaining cases were split among 13 additional provinces in Burundi with cases ranging from 1 to 10 reported per province. Mpox testing data did not include specific geographic residences for individuals. Thus, whether the overrepresentation of cases within Bujumbura Mairie is indicative of local mpox transmission alone, includes non-residents reporting in the province due to healthcare and testing availability, or a combination thereof should be considered.

This report provides an early assessment of the demographic and epidemiological characteristics of Clade Ib mpox cases in Burundi and provide important insights for ongoing outbreak containment and mitigation strategies, including community engagement and messaging activities.

## ETHICS STATEMENT

Data was provided by country-wide mpox surveillance program. Permission to use this data was granted by the Institutional Ethics Committee at the Faculty of Medicine, University of Burundi (CIEB-FMCHUK no. 02/09/2024).

## DATA AVAILABILITY

All data produced in the present study are available upon reasonable request to the authors.

## FUNDING

Funding for the work presented was provided by the International Mpox Research Consortium (IMReC) through funding from the Canadian Institutes of Health Research and International Development Research Centre (grant no. MRR-184813).

## CONFLICT OF INTEREST

IIB consults to the Weapons Threat Reduction Program at Global Affairs Canada.

## REFERENCES

1. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165-82.
2. Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, et al. Human monkeypox. Bull World Health Organ. 1972;46(5):569-76.
3. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593-7.



4. Van Dijck C, Hoff NA, Mbala-Kingebeni P, Low N, Cevik M, Rimoin AW, et al. Emergence of mpox in the post-smallpox era-a narrative review on mpox epidemiology. Clin Microbiol Infect. 2023;29(12):1487-92.
5. Okwor T, Mbala PK, Evans DH, Kindrachuk J. A contemporary review of clade-specific virological differences in monkeypox viruses. Clin Microbiol Infect. 2023;29(12):1502-7.
6. Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New nomenclature for mpox (monkeypox) and monkeypox virus clades. Lancet Infect Dis. 2023;23(3):273-5.
7. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med. 2022;387(8):679-91.
8. WHO. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends. 2023.
9. Tarin-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suner C, Anton A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022;400(10353):661-9.
10. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole A, Wawina-Bokalanga T, Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med. 2024.
11. Mukadi-Bamuleka D K-LE, Mulopo-Mukanya N, Amuri-Aziza A, O'Toole A et al. First imported Cases of MPXV Clade Ib in Goma, Democratic Republic of the Congo: Implications for Global Surveillance and Transmission Dynamics. medRxiv. 2024.

## TABLES

**Table 1: Mpox test results in Burundi by sex.**

	Negative	Indeterminate	Positive
<b>Male</b>	223 (49.8%)	2 (0.33%)	80 (13.2%)
<b>Female</b>	225 (50.2%)	3 (0.49%)	74 (12.2%)
<b>Total</b>	448 (73.8%)	5 (0.82%)	154 (25.4%)



229 **Table 2: Age demographics for individuals tested for mpox in Burundi.**

	<b>Median Age (years)</b> <b>Mpox +ve</b>	<b>Median Age (years)</b> <b>Mpox -ve</b>
<b>Male</b>	17.5 (IQR: 4.8-28.5)	7 (IQR: 2-17.5)
<b>Female</b>	6 (IQR: 2-20)	6 (IQR: 2-14)
<b>Total</b>	9.5 (IQR: 3-25)	6 (IQR: 2-15)

230

231 **Table 3: Age demographics by sex for all individuals with confirmed mpox.**

	<b>All</b>	<b>Male</b>	<b>Female</b>
<b>&lt;15 years</b>	85 (55.2%)	38 (24.7%)	47 (30.5%)
<b>15-30 years</b>	45 (29.2%)	24 (15.6%)	21 (13.6%)
<b>30+ years</b>	24 (15.6%)	18 (11.7%)	6 (3.90%)

232

233 **Table 4: Confirmed mpox cases by province.**

<b>Province</b>	<b>Cases Reported</b>
Bubanza	10 (6.49%)
Bujumbura	10 (6.49%)
Bujumbura Mairie	91 (59.1%)
Bururi	2 (1.30%)
Cibitoke	1 (0.65%)
Gitega	5 (3.25%)
Karusi	3 (1.95%)
Kayanza	10 (6.49%)
Makamba	1 (0.65%)
Muramvya	5 (3.25%)
Muyinga	7 (4.55%)
Mwaro	1 (0.65%)

Rumonge	3 (1.95%)
Ruyigi	5 (3.25%)
<b>Total</b>	154

234

235 **Table 5: Hospitalization data in Burundi up to 25 September 2024.**

	<b>Total Hospitalizations</b>	<b>Median Age (years)</b>	<b>Duration of Care (days)</b>
<b>Male</b>	<b>132</b>	22 (IQR: 8-32)	9 (IQR: 6-12)
<b>Female</b>	<b>115</b>	16 (IQR: 7-25)	8 (IQR: 5-9.8)
<b>Total</b>	<b>247</b>	19 (IQR: 8-28)	8 (IQR: 6-12)

236

237